Product Description: Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 4, 2022.
CAS Number: 2648058-48-2
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: c-Met/HGFR